Breathe Well Live Well
|
Asthma and COPD Therapies Market Forecast 2014-2024: Opportunities for …
Satellite PR News (press release) Where's the asthma and COPD therapies market heading? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there. Our 335-page report provides 264 tables, charts, and graphs. Discover … |
View full post on asthma – Google News
|
Asthma and COPD Therapies Market Forecast 2014-2024: Opportunities for …
PR Newswire (press release) Where's the asthma and COPD therapies market heading? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there. Our 335-page report provides 264 tables, charts, and graphs. Discover … |
View full post on asthma – Google News
|
A Competitive Analysis of the Global Asthma and COPD Therapeutics Market …
MarketWatch oBenralizumab, a monoclonal antibody jointly being developed by MedImmune and AstraZeneca in Phase 3 trials. Benralizumab is bound to the interleukin-5 receptor (IL-5R?) and is being evaluated to help asthma control and reduce the onset of asthmatic … |
View full post on asthma – Google News
|
A Competitive Analysis of the Global Asthma and COPD Therapeutics Market …
PR Newswire (press release) oBenralizumab, a monoclonal antibody jointly being developed by MedImmune and AstraZeneca in Phase 3 trials. Benralizumab is bound to the interleukin-5 receptor (IL-5R?) and is being evaluated to help asthma control and reduce the onset of asthmatic … |
View full post on asthma – Google News
|
Report: U.S. Market for Asthma Treatment to See Modest Growth
Pharmaceutical Processing A new report expects the U.S. market for treatment asthma to grow from $11.7 billion in 2013 to $14 billion by 2020. The analysis by New York-based GBI Research predicted the recent expiration of patents for several of the top current therapeutics … |
View full post on asthma – Google News
|
A Quick Review Of The Asthma Market
Seeking Alpha (registration) Asthma remains a major health concern, with the WHO estimating the number of people suffering from asthma at 235 million. In the U.S., the CDC reports asthma prevalence at 9% in children and 8% in adults (CDC 2012). Even social media trends identify a … |
View full post on asthma – Google News
|
Global COPD and Asthma Devices Market (Product Types and Geography …
PR Newswire (press release) The COPD and Asthma hold the largest market share within the global respiratory diseases' market. As estimated by Global Initiative for Asthma (GINA), approximately 300 million people suffer from Asthma globally. COPD was the 3rd leading cause for … |
View full post on asthma – Google News
|
Asthma Treatment Market (Drug) Worth $23 Billion by 2023
PR Newswire (press release) ReportsnReports.com adds PharmaPoint: Asthma – Global Drug Forecast and Market Analysis to 2023 research report that says asthma treatment market value will grow across eight major countries (the US, UK, France, Germany, Spain, Italy, Japan, and … |
View full post on asthma – Google News
|
COPD and Asthma Devices Market is Expected to Reach $34.3 Billion, Global …
PR Newswire (press release) According to a new report by Allied Market Research titled, "Global COPD and Asthma Devices Market – Size, Industry Analysis, Trends, Opportunities, Growth and Forecast, 2013 – 2020", the global COPD and asthma devices market would reach $34.3 billion … |
View full post on asthma – Google News
|
Research and Markets: GSK's Flovent (Asthma) – Forecast and Market Analysis …
Business Wire (press release) Originally approved by the Food and Drug Administration (FDA) in 1996, GSK's Flovent (fluticasone propionate) is a synthetic ICS therapy with potent anti-inflammatory activity. It is used for the maintenance treatment of asthma prophylactically in … Research and Markets: GSK's Bosatria (Mepolizumab) Asthma Treatment … |
View full post on asthma – Google News